Cover Image
市場調查報告書

神經膠質肉瘤:開發中產品分析

Gliosarcoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245977
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
Back to Top
神經膠質肉瘤:開發中產品分析 Gliosarcoma - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 141 Pages
簡介

神經膠質肉瘤是發生在神經膠細胞的一種腦瘤。這種腦瘤會急速成長,跟據不同部位大小症狀有頭痛、嘔心、認知障礙、昏睡等。治療方法依腫種種類、階段、大小、發生部位、患者年齡及健康狀態而定。

本報告提供神經膠質肉瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

神經膠質肉瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Amgen Inc.
  • Burzynski Research Institute, Inc.
  • Celgene Corporation
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • NewLink Genetics Corporation
  • Sanofi

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • alisertib
  • Antineoplaston Therapy
  • CC-122
  • DNX-2401
  • indoximod
  • lonafarnib
  • Oncolytic Virus to Target IL-12 for Oncology
  • plerixafor
  • rilotumumab
  • SGT-53
  • Stem Cell Therapy for Glioma

開發中產品的最新趨勢

暫停的計劃

開發計劃的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8633IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H2 2016, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 12, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Gliosarcoma.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gliosarcoma Overview
  • Therapeutics Development
    • Pipeline Products for Gliosarcoma - Overview
    • Pipeline Products for Gliosarcoma - Comparative Analysis
  • Gliosarcoma - Therapeutics under Development by Companies
  • Gliosarcoma - Therapeutics under Investigation by Universities/Institutes
  • Gliosarcoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Gliosarcoma - Products under Development by Companies
  • Gliosarcoma - Products under Investigation by Universities/Institutes
  • Gliosarcoma - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Axelar AB
    • Bristol-Myers Squibb Company
    • Burzynski Research Institute, Inc.
    • Celgene Corporation
    • Cortice Biosciences, Inc.
    • ERC Belgium SA
    • Merck & Co., Inc.
    • Millennium Pharmaceuticals Inc
    • NewLink Genetics Corporation
    • Novartis AG
    • Nuo Therapeutics, Inc.
    • Progenics Pharmaceuticals, Inc.
    • Triphase Accelerator Corporation
  • Gliosarcoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALD-451 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antineoplaston Therapy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AXL-1717 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dasatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DNX-2401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ERC-1671 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flucytosine + TBio-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • indoximod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride + TBio-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lonafarnib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-032 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • marizomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • p28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PSMA ADC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rilotumumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RRX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPI-287 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • urelumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gliosarcoma - Dormant Projects
  • Gliosarcoma - Product Development Milestones
    • Featured News & Press Releases
      • Nov 26, 2013: Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gliosarcoma, H2 2016
  • Number of Products under Development for Gliosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Gliosarcoma - Pipeline by Amgen Inc., H2 2016
  • Gliosarcoma - Pipeline by Axelar AB, H2 2016
  • Gliosarcoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Gliosarcoma - Pipeline by Burzynski Research Institute, Inc., H2 2016
  • Gliosarcoma - Pipeline by Celgene Corporation, H2 2016
  • Gliosarcoma - Pipeline by Cortice Biosciences, Inc., H2 2016
  • Gliosarcoma - Pipeline by ERC Belgium SA, H2 2016
  • Gliosarcoma - Pipeline by Merck & Co., Inc., H2 2016
  • Gliosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Gliosarcoma - Pipeline by NewLink Genetics Corporation, H2 2016
  • Gliosarcoma - Pipeline by Novartis AG, H2 2016
  • Gliosarcoma - Pipeline by Nuo Therapeutics, Inc., H2 2016
  • Gliosarcoma - Pipeline by Progenics Pharmaceuticals, Inc., H2 2016
  • Gliosarcoma - Pipeline by Triphase Accelerator Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Gliosarcoma - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Gliosarcoma, H2 2016
  • Number of Products under Development for Gliosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top